Not really sure how it's market sensitive to report it's...

Not really sure how it's market sensitive to report it's compulsory bi-annual survey results (which is ASX decision, not ALT)... nevertheless it seems more confirmation of the product working which is only a positive. I like how they understand the importance of the data in this new data driven world. The data base alone they are building on pelvic issues has sizeable value, so maybe i've talked myself around that it is price sensitive.. or is that my confirmation bias talkin'?